English	French	Notes	Complete/Exclude
23. NUMBER OF TUMORS			
24. DATE OF FIRST SYMPTOMS			
25. DATE OF INITIAL DIAGNOSIS			
26. DATE OF PATHOLOGIC DIAGNOSIS			
27. PRIMARY SITE (ICD-O-2)			
28. WHO HISTOLOGICAL CLASSIFICATION OF TUMOR			
29. BEHAVIOR CODE (ICD-O-2)			
31. DIAGNOSTIC CONFIRMATION			
32. MOLECULAR MARKERS			
33. TUMOR SIZE			
34. TUMOR SIZE (SOURCE			
35. KARNOFSKY'S RATING PRIOR TO THERAPY			
34. TUMOR SIZE (SOURCE)			
 17. CLASS OF CASE.................: 			
1222      CHANGE IN SENSE OF SMELL AND/                                                    OR TASTE....................			
1223      ALTERED ALERTNESS............			
1225      SPEECH DISTURBANCE...........			
1226      PERSONALITY CHANGES..........			
1228      MEMORY LOSS..................			
1229      LACK OF CONCENTRATION........			
1230      DOUBLE VISION................			
1231      OTHER VISUAL DISTURBANCE.....			
1232      DECREASED HEARING............			
1236      WEAKNESS OR PARALYSIS........			
1237      DIFFICULTY IN COORDINATION/                                                      BALANCE.....................			
1238      GENERALIZED SEIZURE..........			
1239      FOOD SEIZURE.................			
1240      BLADDER INCONTINENCE.........			
1241      BOWEL INCONTINENCE...........			
1242      PAIN (OTHER THAN HEADACHE)...			
1243      WEIGHT CHANGE................			
 19. NEUROLOGICAL FINDINGS:			
1248      MEMORY OR JUDGEMENT..........			
1249      VISUAL ACUITY................			
1250      VISUAL FIELDS................			
1251      EYE MOVEMENTS (EOM)..........			
1252      FACIAL SENSATION.............			
1253      FACIAL MOVEMENT..............			
1255      GAG REFLEX...................			
1256      STERNOCLEIDOMASTOID/SHOULDER                                                     SHRUG STRENGTH..............			
1257      ARTICULATION OR ENUNCIATION..			
1259      TONGUE FASCICULATIONS OR                                                         ATROPHY.....................			
1260      DECREASE IN SENSATION OF ANY                                                     SITE........................			
1261      CORTICAL SENSORY DEFICIT.....			
1262      WEAKNESS, ATROPHY OR FASCICULATION                                               OF ANY SITE.................			
1263      ATAXIA OF GAIT...............			
1264      TRUNCAL ATAXIA...............			
1266      RAPID ALTERNATING MOVEMENTS..			
1267      FINGER TO FINGER NOSE TESTING			
1268      HEEL TO KNEE TO SHIN TESTING.			
1269      DEEP TENDON REFLEXES IN UPPER                                                    EXTREMITIES.................			
1270      DEEP TENDON REFLEXES IN LOWER                                                    EXTREMITIES.................			
1271      BABINSKI SIGN................			
1272      HOFFMAN REFLEX...............			
1273      OTHER ABNORMAL REFLEXES......			
 20. PRE-THERAPY DIAGNOSTIC STUDIES:			
1275      CT SCAN OF BRAIN.............			
1276      CT SCAN OF SPINE.............			
1278      ISOTOPE BRAIN SCAN...........			
1279      PET SCAN.....................			
1280      SPECT SCAN...................			
1281      MRI OF BRAIN.................			
1282      MRI OF SPINE.................			
1283      FUNCTIONAL MRI...............			
 21. TUMOR LOCATION/INVOLVEMENT:			
1286      FRONTAL LOBE.................			
1287      TEMPORAL LOBE................			
1288      PARIETAL LOBE................			
1289      OCCIPITAL LOBE...............			
1290      OPTIC NERVES.................			
1291      PITUITARY GLAND..............			
1292      PINEAL GLAND.................			
1294      BRAIN STEM...................			
1295      SKULL BASE...................			
1296      OTHER SKULL..................			
1297      SPINAL CORD..................			
1298      CEREBRAL SPINAL FLUID (CSF)..			
1299      CRANIAL MENINGES.............			
1300      SPINAL MENINGES..............			
1305 23. NUMBER OF TUMORS..............			
1306 24. DATE OF FIRST SYMPTOMS........			
 25. DATE OF INITIAL DIAGNOSIS.....: 			
1307 26. DATE OF PATHOLOGIC DIAGNOSIS..			
 27. PRIMARY SITE (ICD-O-2)........: 			
1308 28. WHO HISTOLOGICAL CLASSIFICATION                                                  OF TUMOR.....................			
 29. BEHAVIOR CODE (ICD-O-2).......: 			
 31. DIAGNOSTIC CONFIRMAITON.......: 			
1309 32. MOLECULAR MARKERS.............			
1394 33. TUMOR SIZE....................			
 34. TUMOR SIZE (SOURCE)...........: Size not recorded			
1310 34. TUMOR SIZE (SOURCE)...........			
1311 35. KARNOFSKY'S RATING PRIOR TO                                                      THERAPY......................			
36. PROTOCOL PARTICIPATION			
37. PROTOCOL PHASE			
38. DATE OF FIRST COURSE TREATMENT			
39. DATE OF INPATIENT ADMISSION			
40. DATE OF INPATIENT DISCHARGE			
41. DATE OF NON CA-DIRECTED SURGERY			
42. DIAGNOSTIC/EVALUATIVE/PALLIATIVE (NON CA-DIRECTED) SURGERY			
43. DATE OF CA-DIRECTED SURGERY			
44. SURGICAL APPROACH			
45. EXTENT OF SURGICAL RESECTION			
46. SIZE OF RESIDUAL PRIMARY TUMOR FOLLOWING CA-DIRECTED SURGERY			
47. SIZE OF RESIDUAL PRIMARY TUMOR FOLLOWING CA-DIRECTED SURGERY (SOURCE)			
48. SURGICAL COMPLICATIONS/POST SURGICAL EVENTS			
49. REASON FOR NO SURGERY			
50. RADIATION THERAPY			
51. DATE RADIATION STARTED			
52. DATE RADIATION ENDED			
53. TOTAL RADIATION DOSE (cGy)			
54. NUMBER OF TREATMENTS TO THIS VOLUME			
55. TYPE OF EXTERNAL BEAM RADIATION			
56. INTERSTITIAL RADIATION/BRACHYTHERAPY			
57. STEREOTACTIC RADIOSURGERY			
58. RADIATION/SURGERY SEQUENCE			
59. RADIATION COMPLICATIONS			
60. REASON FOR NO RADIATION			
61. DATE CHEMOTHERAPY STARTED			
63. TYPE OF CHEMOTHERAPEUTIC AGENTS ADMINISTERED			
64. CHEMOTHERAPEUTIC ROUTE			
65. CHEMOTHERAPY COMPLICATIONS			
66. REASON FOR NO CHEMOTHERAPY			
67. DATE OTHER TREATMENT STARTED			
68. OTHER TREATMENT			
69. KARNOFSKY'S RATING AT TIME OF DISCHARGE/TRANSFER			
1312 36. PROTOCOL PARTICIPATION........			
 37. PROTOCOL PHASE................: Not on			
1313 37. PROTOCOL PHASE................			
 38. DATE OF FIRST COURSE TREATMENT: 			
1 39. DATE OF INPATIENT ADMISSION...			
1.1 40. DATE OF INPATIENT DISCHARGE...			
 41. DATE OF NON CA-DIR SURGERY...: 			
 42. DIAGNOSTIC/EVALUATIVE/PALLIATIVE (NON CA-DIRECTED) SURGERY:			
      NONE, NO NON CA-DIRECTED SURGICAL PROCEDURE...: Yes			
      VENTRICULOSTOMY, OR EXTERNAL VENTRICULAR DRAIN: No			
      CSF SHUNT, VENTRICULOPERITONEAL...............: No			
      CSF SHUNT, THIRD VENTRICULOSTOMY..............: No			
      CSF SHUNT, OTHER..............................: No			
      STEREOTACTIC BIOPSY...........................: No			
      OPEN BRAIN BIOPSY.............................: No			
      OPEN BIOPSY OF SPINAL CORD TUMOR..............: No			
      LAMINECTOMY FOR SPINAL CORD TUMOR,                                               W/O TUMOR RESECTION, W/O OPENING DURA........: No			
      UNKNOWN IF SURGERY DONE.......................: No			
      NONE, NO NON CA-DIRECTED                                                         SURGICAL PROCEDURE..........: No			
1314      NONE, NO NON CA-DIRECTED                                                         SURGICAL PROCEDURE..........			
1315      VENTRICULOSTOMY, OR EXTERNAL                                                     VENTRICULAR DRAIN...........			
1316      CSF SHUNT,                                                                       VENTRICULOPERITONEAL........			
1317      CSF SHUNT,                                                                       THIRD VENTRICULOSTOMY.......			
1318      CSF SHUNT,                                                                       OTHER.......................			
1319      STEREOTACTIC BIOPSY..........			
1320      OPEN BRAIN BIOPSY............			
1321      OPEN BIOPSY OF SPINAL CORD                                                       TUMOR.......................			
1322      LAMINECTOMY FOR SPINAL CORD TUMOR,                                               W/O TUMOR RESECTION,                                                             W/O OPENING DURA...........			
1323      LAMINECTOMY FOR SPINAL CORD TUMOR,                                               W/O TUMOR RESECTION,                                                             W OPENING DURA.............			
1325      UNKNOWN IF SURGERY DONE......			
 43. DATE OF CA-DIRECTED SURGERY...: 			
 44. SURGICAL APPROACH.............: None, no ca-directed surgery			
 45. EXTENT OF SURGICAL RESECTION..: None, no surgery performed			
 46. SIZE OF RESIDUAL PRIMARY TUMOR                                                   AFTER CA-DIR SURGERY.........: NA, surgical treatment not administered			
 47. SIZE OF RESIDUAL PRIMARY TUMOR                                                   AFTER CA-DIR SURGERY (SOURCE): Size not recorded			
 48. SURGICAL COMPLICATIONS/POST SURGICAL EVENTS:			
      ANESTHETIC PROBLEM...........: NA, surgery not performed			
      HEMORRHAGE AT OPERATIVE SITE.: NA, surgery not performed			
      SEIZURE......................: NA, surgery not performed			
      INFECTION(S).................: NA, surgery not performed			
      DVT (DEEP VENOUS THROMBOSIS..: NA, surgery not performed			
      PERSISTENT NEUROLOGICAL WORSENING                                                OVER 4 DAYS POST-OP.........: NA, surgery not performed			
      OTHER........................: NA, surgery not performed			
 44. SURGICAL APPROACH.............: Surgical approach unknown			
 45. EXTENT OF SURGICAL RESECTION..: Unknown if surgery performed			
      ANESTHETIC PROBLEM...........: Unknown			
      HEMORRHAGE AT OPERATIVE SITE.: Unknown			
      DVT (DEEP VENOUS THROMBOSIS..: Unknown			
1326 44. SURGICAL APPROACH.............			
1327 45. EXTENT OF SURGICAL RESECTION..			
1328 46. SIZE OF RESIDUAL PRIMARY TUMOR                                                   AFTER CA-DIR SURGERY.........			
1329 47. SIZE OF RESIDUAL PRIMARY TUMOR                                                   AFTER CA-DIR SURGERY (SOURCE)			
1330      ANESTHETIC PROBLEM...........			
1331      HEMORRHAGE AT OPERATIVE SITE.			
1334      DVT (DEEP VENOUS THROMBOSIS).			
1335      PERSISTENT NEUROLOGICAL WORSENING                                                OVER 4 DAYS POST-OP.........			
58 49. REASON FOR NO SURGERY.........			
 50. RADIATION THERAPY.............: None			
 51. DATE RADIATION STARTED........: 			
 52. DATE RADIATION ENDED..........: 00/00/0000			
 53. TOTAL RADIATION DOSE (cGy)....: No radiation administered			
 54. NUMBER OF TREATMENTS TO THIS                                                     VOLUME.......................: 			
 55. TYPE OF EXT BEAM RADIATION....: No radiation therapy			
 56. INTERSTITIAL RAD/BRACHYTHERAPY: None, brachytherapy not given			
 57. STEREOTACTIC RADIOSURGERY.....: None, not administered			
 58. RADIATION/SURGERY SEQUENCE....: 			
 59. RADIATION COMPLICATIONS:			
      SKIN REACTIONS...............: NA, radiation tx not administered			
      ANOREXIA.....................: NA, radiation tx not administered			
      NAUSEA OR VOMITING...........: NA, radiation tx not administered			
      FATIGUE......................: NA, radiation tx not administered			
      NEUROLOGIC WORSENING.........: NA, radiation tx not administered			
 50. RADIATION THERAPY.............: Unk, death cert cases only			
 52. DATE RADIATION ENDED..........: 99/99/9999			
 53. TOTAL RADIATION DOSE (cGy)....: Dose unknown			
 55. TYPE OF EXT BEAM RADIATION....: Unknown			
 56. INTERSTITIAL RAD/BRACHYTHERAPY: Unknown			
 57. STEREOTACTIC RADIOSURGERY.....: Unknown			
      SKIN REACTIONS...............: Unknown			
      NAUSEA OR VOMITING...........: Unknown			
      NEUROLOGIC WORSENING.........: Unknown			
1345 50. RADIATION THERAPY.............			
361 52. DATE RADIATION ENDED..........			
1336 53. TOTAL RADIATION DOSE (cGy)....			
56 54. NUMBER OF TREATMENTS TO THIS                                                     VOLUME...................... 			
1337 55. TYPE OF EXT BEAM RADIATION....			
1338 56. INTERSTITIAL RAD/BRACHYTHERAPY			
1339 57. STEREOTACTIC RADIOSURGERY.....			
51.3 58. RADIATION/SURGERY SEQUENCE....			
1340      SKIN REACTIONS...............			
1342      NAUSEA OR VOMITING...........			
1344      NEUROLOGIC WORSENING.........			
75 60. REASON FOR NO RADIATION.......			
 61. DATE CHEMOTHERAPY STARTED.....: 			
 63. TYPE OF CHEMOTHERAPEUTIC AGENTS ADMINISTERED:			
      PROCARBAZINE.................: NA, chemotherapy not administered			
      CCNU.........................: NA, chemotherapy not administered			
      VINCRISTINE..................: NA, chemotherapy not administered			
      HYDROXYUREA..................: NA, chemotherapy not administered			
      METHOTREXATE.................: NA, chemotherapy not administered			
      CISPLATIN....................: NA, chemotherapy not administered			
      BCNU.........................: NA, chemotherapy not administered			
      BCNU WAFER IMPLANT...........: NA, chemotherapy not administered			
      VP-16........................: NA, chemotherapy not administered			
      CARBOPLATIN..................: NA, chemotherapy not administered			
      TEMOZOLOMIDE.................: NA, chemotherapy not administered			
      CYCLOPHOSPHAMIDE.............: NA, chemotherapy not administered			
      CPT-11.......................: NA, chemotherapy not administered			
      TAMOXIFEN....................: NA, chemotherapy not administered			
      INTERFERON...................: NA, chemotherapy not administered			
      CYTARABINE (ARA-C)...........: NA, chemotherapy not administered			
      OTHER........................: NA, chemotherapy not administered			
      BCNU WAFER IMPLANT...........: Unknown			
1351      BCNU WAFER IMPLANT...........			
 64. CHEMOTHERAPEUTIC ROUTE........: NA, chemotherapy not administered			
 64. CHEMOTHERAPEUTIC ROUTE........: Unknown			
1358 64. CHEMOTHERAPEUTIC ROUTE........			
 65. CHEMOTHERAPY COMPLICATIONS:			
      HEARING LOSS.................: NA, chemotherapy not administered			
      INFECTION....................: NA, chemotherapy not administered			
      NAUSEA AND VOMITING REQUIRING                                                   CESSATION OF CHEMOTHERAPY....: NA, chemotherapy not administered			
      PERIPHERAL BLOOD COUNT DROP/                                                     BLEEDING/CESSATION OF CHEMO-                                                     THERAPY AND/OR TRANSFUSION.: NA, chemotherapy not administered			
      PERIPHERAL NEUROPATHY........: NA, chemotherapy not administered			
      RENAL FAILURE................: NA, chemotherapy not administered			
      PULMONARY TOXICITY...........: NA, chemotherapy not administered			
      HEARING LOSS.................: Unknown			
      PERIPHERAL NEUROPATHY........: Unknown			
      RENAL FAILURE................: Unknown			
      PULMONARY TOXICITY...........: Unknown			
1359      HEARING LOSS.................			
1361      NAUSEA AND VOMITING REQUIRING                                                    CESSATION OF CHEMOTHERAPY...			
1362      PERIPHERAL BLOOD COUNT DROP/                                                     BLEEDING/CESSATION OF CHEMO-                                                     THERAPY AND/OR TRANSFUSION.			
1363      PERIPHERAL NEUROPATHY........			
1364      RENAL FAILURE................			
1365      PULMONARY TOXICITY...........			
76 66. REASON FOR NO CHEMOTHERAPY....			
 67. DATE OTHER TREATMENT STARTED..: 			
 68. OTHER TREATMENT...............: 			
1367 69. KARNOFSKY'S RATING AT TIME OF                                                    DISCHARGE/TRANSFER...........			
70. DATE OF FIRST RECURRENCE			
71. TYPE OF FIRST RECURRENCE			
72. DATE OF PROGRESSION			
73. TYPE OF PROGRESSION			
74. RECURRENCE/PROGRESSION DOCUMENTATION			
75. KARNOFSKY'S RATING AT TIME OF RECURRENCE/PROGRESSION			
70. TYPE OF FIRST RECURRENCE			
71. DATE OF FIRST RECURRENCE			
70 70. DATE OF FIRST RECURRENCE......			
1372 71. TYPE OF FIRST RECURRENCE......			
1368 72. DATE OF PROGRESSION...........			
1369 73. TYPE OF PROGRESSION...........			
 74. RECURRENCE/PROGRESSION                                                           DOCUMENTATION................: No recurrence/progession			
1370 74. RECURRENCE/PROGRESSION                                                           DOCUMENTATION................			
 75. KARNOFSKY'S RATING AT TIME OF                                                    RECURRENCE/PROGRESSION.......: 888			
1371 75. KARNOFSKY'S RATING AT TIME OF                                                    RECURRENCE/PROGRESSION.......			
76. DATE OF SUBSEQUENT TREATMENT FOR RECURRENCE/PROGRESSION			
77. PROTOCOL PARTICIPATION (SUBSEQUENT TREATMENT)			
78. TYPE OF SUBSEQUENT SURGICAL TREATMENT FOR RECURRENCE/PROGRESSION			
79. TYPE OF SUBSEQUENT RADIATION TREATMENT FOR RECURRENCE/PROGRESSION			
80. TYPE OF SUBSEQUENT CHEMOTHERAPY FOR RECURRENCE/PROGRESSION			
81. OTHER TYPE OF SUBSEQUENT TREATMENT FOR RECURRENCE/PROGRESSION			
 SUBSEQUENT TREATMENT			
 76. DATE OF SUBSEQUENT TREATMENT                                                     FOR RECURRENCE/PROGRESSION...: 			
 77. PROTOCOL PARTICIPATION                                                           (SUBSEQUENT TREATMENT).......: Not on			
1373 77. PROTOCOL PARTICIPATION                                                           (SUBSEQUENT TREATMENT).......			
 78. TYPE OF SUBSEQUENT SURGICAL TX                                                   FOR RECURRENCE/PROGRESSION...: None, no subsequent surgery			
1374 78. TYPE OF SUBSEQUENT SURGICAL TX                                                   FOR RECURRENCE/PROGRESSION...			
 79. TYPE OF SUBSEQUENT RADIATION TX                                                  FOR RECURRENCE/PROGRESSION...: None			
1375 79. TYPE OF SUBSEQUENT RADIAITON TX                                                  FOR RECURRENCE/PROGRESSION...			
 80. TYPE OF SUBSEQUENT CHEMOTHERAPY FOR RECURRENCE/PROGRESSION:			
      Chemotherapy not administered			
      PROCARBAZINE.......: NA        CARBOPLATIN........: NA			
      CCNU...............: NA        TEMOZOLOMIDE.......: NA			
      VINCRISTINE........: NA        CYCLOPHOSPHAMIDE...: NA			
      HYDROXYUREA........: NA        CPT-11.............: NA			
      METHOTREXATE.......: NA        TAMOXIFEN..........: NA			
####################	####################	####################	
####################	####################	####################	
####################	####################	####################	
####################	####################	####################	
####################	####################	####################	
